Forair 125/Forair 250

Forair 125/Forair 250

salmeterol + fluticasone


Cadila Healthcare


Metro Drug


Zydus Healthcare Phils
Concise Prescribing Info
Per 25/125 mcg MDI Salmeterol xinafoate 25 mcg, fluticasone propionate 125 mcg. Per 25/250 mcg MDI Salmeterol xinafoate 25 mcg, fluticasone propionate 250 mcg
Regular treatment of asthma & airflow obstruction in patients w/ COPD associated w/ chronic bronchitis.
Dosage/Direction for Use
Adult & adolescent ≥12 yr 2 inhalations bid.
Acute bronchospasm. Primary treatment of status asthmaticus or other acute episodes.
Special Precautions
Avoid abrupt w/drawal. Pulmonary TB, severe CV disorders including heart rhythm abnormalities, existing or history of DM, untreated hypokalemia or thyrotoxicosis. Discontinue use if paradoxical bronchospasm occurs. Increased risk of systemic effects w/ high doses for prolonged period & concomitant use w/ other potent CYP3A4 inhibitors. Regularly monitor height of childn during prolonged use. Pregnancy & lactation. Elderly.
Adverse Reactions
Nausea, dizziness, arthralgia, rash, hyperglycemia. Hoarseness of voice/dysphonia, throat irritation, headache, candidiasis of the mouth & throat. Adrenal suppression, decreased bone mineral density.
Drug Interactions
Increased plasma conc w/ ritonavir. TCAs, MAOIs, β-adrenergic receptor blockers, thiazide or K-depleting diuretics, ketoconazole or CYP450 inhibitors.
ATC Classification
R03AK06 - salmeterol and fluticasone ; Belongs to the class of adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics. Used in the treatment of obstructive airway diseases.
Forair 125 MDI
1's (P385/canister)
Forair 250 MDI
1's (P548/canister)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in